Temocillin in cystic fibrosis: A retrospective pilot study

Lisa Kent, Judy Bradley, Megan France, Gerd Doring, Stephane Carryn, Ian Bradbury, Jackie Rendall, Andrew Jones, J. Stuart Elborn

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)


    Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p
    Original languageEnglish
    Pages (from-to)551-554
    JournalJournal of Cystic Fibrosis
    Issue number6
    Publication statusPublished (in print/issue) - Nov 2008


    • Temocillin
    • Burkholderia cepacia complex
    • Pseudomonas aeruginosa


    Dive into the research topics of 'Temocillin in cystic fibrosis: A retrospective pilot study'. Together they form a unique fingerprint.

    Cite this